Replies to post #245408 on Biotech Values

[semi_infinite]

Must be anticipated, IONS down more than ARWR for whatever reason.

[dewophile]

HBV
This is not altogether surprising after AASLD data came out

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170351524

We're getting closer to answering the question you posed in https://investorshub.advfn.com/boards/replies.aspx?msg=169241666

Whether siRNA or antisense is better suited to knocking down HBsAg remains an open question

[DewDiligence]

ARWR climbs on the obesity bandwagon:

https://www.businesswire.com/news/home/20240814618768/en

Arrowhead Pharmaceuticals…today presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of obesity and metabolic diseases.

In preclinical studies to date, these candidates demonstrated the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass compared to currently approved obesity therapies.

Arrowhead plans to submit clinical trial applications with regulatory authorities for both programs by the end of 2024 with the goal of initiating clinical studies in volunteers with obesity in early 2025.

Quite a few companies are making these kinds of claims about muscle preservation based on preclinical data.